Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.

JANUVIA is a selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances a natural body system, called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. JANUVIA is the first and only DPP-4 inhibitor to be approved and marketed in the United States for patients with type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus. JANUVIA is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in patients with type 2 diabetes when the single agent alone plus diet and exercise do not provide adequate glycemic control. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...ant Reductions in Selected ...in 2008 Proceedings of the American Society of ...GO, May 16 /- ADVENTRX Phar...at, in a registrational bioequivalence,clinical st...ant reduction,in general disorders and administrat...
(Date:5/15/2008).../ -- Medivation, Inc.,(Nasdaq: MDVN ) today annou...trial of its novel androgen receptor antagonist, M...at the 44th American Society of Clinical Oncology,...e: New Targeted Strategies for Patients with Prost...at 11:30 a.m. Central Time Abstract title: "Phase...
(Date:5/15/2008)...rstCall/ -- Cytopia Limited,(ASX: CYT) today annou...ntation on CYT997 at the 2008 Annual Meeting of th...l be accessible to the public via ASCO,s,website ... (US EDT)., The oral presentation, entitled "Phas...scular disrupting agent, in patients with advanced...
Breaking Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Cleveland Clinic Press Releases Book About a Surgeons Mission to Perform the Worlds First Full Face Transplant 11690 1Cleveland Clinic Press Releases Book About a Surgeons Mission to Perform the Worlds First Full Face Transplant 11690 2Neuromusic showtime 11688 1Neuromusic showtime 11688 2Neuromusic showtime 11688 3USHEALTH Group Announces Appointment of Executive Vice President 11684 1USHEALTH Group Announces Appointment of Executive Vice President 11684 2BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 1BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 2BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 3BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 4BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 5BioElectronics Corporation 28BIEL 29 SqueezeTrigger Price is 240 11 11680 6
(Date:5/16/2008)... BENSALEM, Pa., May 16 /PRNewswire/ -- Law Offi...eadline to move to be a lead plaintiff in the,secu... persons who,purchased or otherwise acquired the c... ("Inverness Medical" or the "Company") (Amex: IM...or about November 14, 2007 (the,"Class Period"). T...
(Date:5/16/2008)... Month-long Campaign to Emphasize the Importance o...6 /PRNewswire/ -- National dental insurer United,C...h, a collaboration,between Oral Health America and...he importance of oral health to overall health. Be...the United States for the first time,making it th...
(Date:5/16/2008)... (Washington) Declaring that Primary care medici... FACP, president of the American College of Physic...ives of employers and consumers to issue a call fo...tain general internists and other primary care phy...te of primary care medicine in the U.S., Dr. Dale ...
(Date:5/16/2008)... Live Web Cast Scheduled for May 19 at 10:15...-FirstCall/ - Response Biomedical,Corporation (TSX... Kay,Chief Executive Officer, is scheduled to pre...lthcare Conference on Monday May 19th at 10:15 a.m...be available on the Company,s,Web site at, http://...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:United Concordia Dental Celebrates National Smile Month 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
...According to a new research, implants to aid heari...m. Hearing loss affects around a quarter of all ad...lly there was one option for those with a hearing ...Now, however, there's another choice - an implant ...
...A new research suggests that the patients who unde...ased risk of later developing pancreatic cancer. T...s of 2,000 patients who underwent an operation kno...rs.// Peptic ulcers are sores located in the linin...
...Yale researchers found that radiant-light therapy ...egnant women. Dr. Dan Oren, an associate professor...ew Jersy, felt that the availability of an easy-to...sant light therapy in pregnancy is a clinically at...
...A Queensland group have developed an efficient met... help to manage outbreaks of diseases such as meni...re for Diagnostics, based at Queensland University...ew technologies// that have emerged in the area of...
Other Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available.
... IDT 16 is Philips premium 16-slice CT scanner. F...ed to automatically delivering high quality, advan...direction in a platform that has been the most pop...sive organ assessment literally within seconds, an...
...nstrument set consists of modular reamers and broa...or bone graft channel preparation. Developed for r... cage. These instruments provide proper channel pr... and optimal contact with the vertebral endplates....
... Dilation Port enables the surgeon to perform a tr...vasive approach using step dilation. Using a serie... creating space for a custom-sized working surgica...erate with a traditional surgical technique by pro...
Medicine Products: